Andrew Q. Viet

Development of Dihydropyridone Indazole Amides as Selective Rho-Kinase Inhibitors

Krista Goodman, Haifeng Cui, Sarah E. Dowdell et al. · Journal of Medicinal Chemistry · 2006 · 154 citations · Full text

Indazole Substitution, Medicinal Chemistry, Oral Bioavailability +11

Potent, Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as Potential Therapeutic Agents for Cardiovascular Diseases

Clark A. Sehon, Gren Z. Wang, Andrew Q. Viet et al. · Journal of Medicinal Chemistry · 2008 · 72 citations · Full text

Medicinal Chemistry, Potential Therapeutic Agents, Biochemistry +15

Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity

Robert A. Stavenger, Haifeng Cui, Sarah E. Dowdell et al. · Journal of Medicinal Chemistry · 2006 · 71 citations · Full text

Drug Target, Bioorganic Chemistry, Pharmacotherapy +18

Triazolopyrimidines identified as reversible myeloperoxidase inhibitors

Franck Duclos, Lynn M. Abell, David Harden et al. · MedChemComm · 2017 · 29 citations

Potent Triazolopyridine Myeloperoxidase Inhibitors

Nicholas R. Wurtz, Andrew Q. Viet, Scott A. Shaw et al. · ACS Medicinal Chemistry Letters · 2018 · 28 citations · Full text